EGFR Inhibitor-Induced Skin Rash

Clinical trial pipeline · Data from ClinicalTrials.gov

See which EGFR Inhibitor-Induced Skin Rash trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06818058

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive e…

France60 participantsStarted 2025-01-20

Treatment: Brimonidine tartrate Gel, Placebo gel (no Brimonidine tartrate)

All recent trials (9 shown)

CompletedEarly Phase 1

NCT03471364

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoc…

United States58 participantsStarted 2018-09-25

Treatment: Ketoconazole, Laboratory Biomarker Analysis

UnknownPhase 2

NCT04759664

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorect…

United States117 participantsStarted 2021-04-12

Treatment: LUT014 Gel (Dose 1), LUT014 Gel (Dose 2)

EGFR Inhibitor-Induced Skin Rash

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

All recent trials (9 shown)

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

All recent trials (9 shown)

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream